Search

Your search keyword '"Bander, Neil"' showing total 13 results
Start Over Author "Bander, Neil" Publisher wolters kluwer uk
13 results on '"Bander, Neil"'

1. PD01-11 PHASE I DOSE-ESCALATION TRIAL OF MULTIPLE AND FRACTIONATED-DOSE PSMA-TARGETED ALPHA RADIONUCLIDE (225AC-J591) FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.

Author

Sun, Michael, Nauseef, Jones, Fajardo, Andrés Ricaurte, Davidson, Zachary, Thomas, Joseph, Ruder, Samuel, Stangl-Kremser, Judith, Castellanos, Sandra Huicochea, Molina, Ana, Sternberg, Cora, Patel, Amie, Yuan, Sarah, Fernandez, Escarleth, Fung, Edward, Avlonitis, Vasilios, O'Dwyer, Elisabeth, Nanus, David, Osborne, Joseph, Bander, Neil, and Tagawa, Scott

Subjects
CASTRATION-resistant prostate cancer, RADIOISOTOPES, LINEAR energy transfer
Published
2024
Full Text
View/download PDF

2. A Prospective Pilot Study of 89Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy.

Author

Osborne, Joseph R., Green, David A., Spratt, Daniel E., Lyashchenko, Serge, Fareedy, Shoaib B., Robinson, Brian D., Beattie, Bradley J., Jain, Manu, Lewis, Jason S., Christos, Paul, Larson, Steven M., Bander, Neil H., and Scherr, Douglas S.

Subjects
POSITRON emission tomography, PROSTATE cancer treatment, PROSTATECTOMY, DIAGNOSTIC imaging, PROSTATE-specific antigen, PREOPERATIVE care, MAGNETIC resonance imaging
Abstract

Purpose: In this pilot study we explored the feasibility of 89Zr labeled J591 monoclonal antibody positron emission tomography of localized prostate cancer. Materials and Methods: Before scheduled radical prostatectomy 11 patients were injected intravenously with 89Zr-J591, followed 6 days later by whole body positron emission tomography. Patients underwent surgery the day after imaging. Specimens were imaged by ex vivo micro positron emission tomography and a custom 3 Tesla magnetic resonance scanner coil. Positron emission tomography images and histopathology were correlated. Results: Median patient age was 61 years (range 47 to 68), median prostate specific antigen was 5.2 ng/ml (range 3.5 to 12.0) and median biopsy Gleason score of the 11 index lesions was 7 (range 7 to 9). On histopathology 22 lesions were identified. Median lesion size was 5.5 mm (range 2 to 21) and median Gleason score after radical prostatectomy was 7 (range 6 to 9). Eight of 11 index lesions (72.7%) were identified by in vivo positron emission tomography. Lesion identification improved with increasing lesion size for in vivo and ex vivo positron emission tomography (each p <0.0001), and increasing Gleason score (p = 0.14 and 0.01, respectively). Standardized uptake values appeared to correlate with increased Gleason score but not significantly (p = 0.19). Conclusions: To our knowledge this is the first report of 89Zr-J591/prostate specific membrane antigen positron emission tomography in localized prostate cancer cases. In this setting 89Zr-J591 bound to tumor foci in situ and positron emission tomography identified primarily Gleason score 7 or greater and larger tumors, likely corresponding to clinically significant disease warranting definitive therapy. A future, larger clinical validation trial is planned to better define the usefulness of 89Zr-J591 positron emission tomography for localized prostate cancer. [Copyright &y& Elsevier]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results